FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Dorsch Marion						2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ]									all app Direc	licable)	ng Person(s) to Is 10% Ov Other (s		wner
	(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET						3. Date of Earliest Transaction (Month/Day/Year) 03/23/2020								below		ntific	below)	
(Street) CAMBRIDGE MA 02139				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	′					
(City)	(St	ate) (2	Zip)																
		Table	I - No	on-Deriva	tive \$	Secui	rities	Acc	uired	l, Dis	sposed of	, or Be	enefic	ially	Own	ed			
Date				2. Transacti Date (Month/Day	Execut (Year) if any		Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,			1 and 5) Secur Benef Owne		cially I Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	Amount	(A) or (D)	Price		Transa	Reported Transaction(s) (Instr. 3 and 4)			(111501.4)			
Common Stock 03/23/2						)20					199	D	\$55.1	L <b>4</b> <sup>(2)</sup>	16,265			D	
Common Stock 03/23/20						20					241	D	\$53.4	13 <sup>(3)</sup>	16,024			D	
Common Stock 03/23/20					)20				S <sup>(1)</sup>		774	D	\$51.5	52 <sup>(4)</sup> 1		15,250		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		of Deriv	r osed ) r. 3, 4	6. Date Expira (Montl	tion D		7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4)		Der Sec	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date		Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Effected pursuant to a trading plan adopted on April 3, 2019 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$55.00 to \$55.27 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$53.41 to \$53.58 per share.
- 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.01 to \$51.93 per share.

/s/ Christopher Frankenfield,

Attorney-in-Fact

03/25/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.